1997
DOI: 10.1016/s0016-5107(97)80028-4
|View full text |Cite
|
Sign up to set email alerts
|

Argon plasma coagulation: Comparison to other candidate therapies for barrett's ablation using the canine esophagus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0
1

Year Published

1999
1999
2003
2003

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 0 publications
0
2
0
1
Order By: Relevance
“…In all but one patient, esophageal acid exposure was normalized following fundoplication. Endoscopic ablation of the Barrett's mucosa was performed by APC technique (Erbe, Tubingen, Germany) using 30-50 W setting as suggested by Heler et al [9]. The APC beams were applied starting from the squamocolumnar junction and proceeding to the gastroesophageal junction.…”
Section: Experimental Designmentioning
confidence: 99%
“…In all but one patient, esophageal acid exposure was normalized following fundoplication. Endoscopic ablation of the Barrett's mucosa was performed by APC technique (Erbe, Tubingen, Germany) using 30-50 W setting as suggested by Heler et al [9]. The APC beams were applied starting from the squamocolumnar junction and proceeding to the gastroesophageal junction.…”
Section: Experimental Designmentioning
confidence: 99%
“…Early animal studies reveal that argon plasma coagulation, another noncontact electrocautery method, may also become a viable option for ablation of Barrett's epithelium. 45 It is important to note that in some cases ablation therapy has led to reepithelialization over intestinal metaplasia. The potential exists that this epithelium may still harbor a neoplastic risk.…”
Section: New Techniques For the Treatment Of Barrett's Esophagusmentioning
confidence: 99%
“…Com o conhecimento dos trabalhos experimentais de Keier et al 58 As pesquisas parecem corroborar a idéia de que talvez fosse melhor tratar o EB, já que ainda não há um marcador genético confiável que permita selecionar quem vai ou não, ter displasia e câncer. Parece haver também provas de que a supressão ácida não impediria o aparecimento da displasia e do câncer em pacientes com mutação do p53, mas esse exame ainda é pouco disponível, caro e não apresenta provas incontestes de sua especificidade e acurácia.…”
unclassified